Phase II study of biweekly cetuximab and irinotecan for unresectable advanced/recurrent colorectal cancer. Phoenix study
Phase 2
Recruiting
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000003483
- Lead Sponsor
- Kitasato University East Hospital Department of gastroenterological surgery, Department of gastroenterology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
Not provided
Exclusion Criteria
1.severe heart disease. 2.severe liver disease. 3.severe lung disease. 4.active gastrointestinal bleeding. 5.severe mental disease. 6.severe diabetes/. 7.ileus. 8.active infectious disease. 9.other active cancer. 10.cerebral metastasis. 11.icterus 12.severe diarrhea. 13.severe allergic reaction for drugs 14.massive ascites, plerural effusion. 15.under treatment with atazanavir 16.a pregnant woman, a woman in breast-feeding, a man who expects his baby. 17.an inappropriate case judged by docter in charge.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method